Effect of a Daily Supplement on Plasma PAI-1 Levels
Running, not enrolling · Phase 1/Phase 2
Conditions studied: Aging, Endothelial Dysfunction, Senescence
In brief
In a healthy person, the production of nitric oxide (NO) by the endothelium, the inner lining of the blood vessel, is responsible for a) the ability of the blood vessel to dilate so it can increase its blood flow and b) act as an anti-clotting product to prevent blood clotting in those vessels. Under physiological stress either due to the development of a disease such as diabetes or simply from aging, the endothelial cells can be impacted and become dysfunctional, thereby impairing their ability to make NO and even promoting the development of blood clots. When such endothelial dysfunction occurs, it may be a precursor for the future development of cardiovascular (CV) disease like hypertension or coronary artery disease later on in life in these patients. Therefore, the ability to enhance the local production or availability of NO within such affected blood vessels in patients identified as prone to endothelial dysfunction could play a positive role in either preventing or delaying the onset of endothelial dysfunction and subsequent CV disease in such patients. RM is an oral supplement consisting of natural ingredients and the amino acid, L-citrulline. In laboratory experiments with cells from the inner lining of blood vessels, the four components of RM have been shown to increase the concentration of NO and decrease the levels of some aging markers. In our recently completed study (manuscript currently in review), 31 young men and women took the supplement for 14 days and had no serious side effects. The supplement caused the expected potentially beneficial dilation of the blood vessels and decrease in the levels of Plasminogen Activator Inhibitor-1 (PAI-1), whose levels correlate with aging and risk of cardiovascular disease. In this study, healthy participants will consume the supplement for a 6-week period to determine if PAI-1 levels continue to be suppressed and also examine whether the supplement has an effect on other blood markers whose levels can change with aging or cardiovascular disease and may also be indicative or predictive of an illness.
Key facts
- Study ID
- NCT07469475
- Run by
- University of California, Los Angeles
- People needed
- 35
- Starts
- 2026-02-24
- Expected to finish
- 2026-12-01
- Last updated by the study team
- 2026-06-25
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- People of any gender at least 18 years of age who do not have a history of acute or chronic cardiovascular illnesses are eligible.
You may not qualify if…
- Younger than 18 years of age
- Currently pregnant (which will be confirmed by pregnancy test for participants capable of pregnancy)
- Using hormonal birth control
- Current smoker
- Allergy to ginger, muira puama, Paullinia cupana, or L-citrulline
- Previous use of Revactin® or RM
- History of serious cardiovascular events, including myocardial infarction (heart attack) or stroke
- History of coronary, cardiac, or carotid surgery such as a stent, heart surgery, or endarterectomy
- Active cancer of any type other than skin cancer
Where it is running
- UCLA — Los Angeles, California, United States
- UCLA The Men's Clinic — Santa Monica, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.